Last updated: September 7, 2026
Urofollitropin is a urinary-derived follicle-stimulating hormone used in controlled ovarian stimulation, ovulation induction, and assisted reproductive technology. Its commercial position has weakened sharply in the United States following the withdrawal of Ferring’s Bravelle product and the shift toward recombinant FSH products, including follitropin alfa and follitropin beta. Urofollitropin remains commercially relevant in selected international fertility markets, but public financial disclosures do not identify product-level revenue.
The principal investment conclusion is that urofollitropin is a mature, price-sensitive fertility product rather than a high-growth biologic. Its market trajectory depends on regional availability, physician preference, procurement pricing, and competition from recombinant gonadotropins. Patent protection is unlikely to be the primary commercial barrier in major markets. Manufacturing consistency, regulatory registrations, brand relationships, and distribution access are more important.
What is urofollitropin and how is it used?
Urofollitropin is highly purified urinary FSH. It stimulates ovarian follicular development and is administered by injection during controlled ovarian stimulation. It is used in women with ovulatory dysfunction and in protocols for in vitro fertilization and related assisted reproductive technologies.
Urofollitropin differs from recombinant FSH because its active hormone is extracted and purified from the urine of postmenopausal women. Recombinant products are manufactured using genetically engineered cell lines. Both product classes deliver FSH activity, but they differ in manufacturing, impurity profiles, supply chains, regulatory history, and pricing.
Common clinical uses include:
- Controlled ovarian stimulation for IVF.
- Ovulation induction in anovulatory patients.
- Stimulation before oocyte retrieval.
- Combination treatment with human chorionic gonadotropin or gonadotropin-releasing hormone protocols.
Dosage is individualized according to ovarian reserve, age, response to stimulation, and the treatment protocol. The principal safety concern is ovarian hyperstimulation syndrome, along with multiple gestation and thromboembolic complications in susceptible patients.
What products contain urofollitropin?
The best-known U.S. product was Bravelle, marketed by Ferring Pharmaceuticals. International products include Fostimon and other urofollitropin products marketed under country-specific names and registrations.
| Product |
Active ingredient |
Representative company |
Market position |
| Bravelle |
Urofollitropin |
Ferring Pharmaceuticals |
U.S. product withdrawn from commercial distribution |
| Fostimon |
Urofollitropin |
International regional marketers, including IBSA-associated operations in certain markets |
Available in selected non-U.S. markets |
| Gonal-f |
Follitropin alfa |
Merck Serono |
Recombinant FSH competitor |
| Follistim AQ |
Follitropin beta |
Organon |
Recombinant FSH competitor |
| Bemfola |
Follitropin alfa biosimilar |
Gedeon Richter and regional partners |
Lower-cost recombinant competitor in Europe and other markets |
| Ovaleap |
Follitropin alfa biosimilar |
Theramex and regional partners |
Recombinant FSH competitor in selected markets |
Product availability differs by country. A urofollitropin product approved in Europe, Latin America, Asia, or the Middle East does not establish current U.S. market access.
What is the FDA status of urofollitropin?
The FDA-approved U.S. urofollitropin product was Bravelle, approved under New Drug Application 021306. Ferring discontinued Bravelle after a product recall and subsequent manufacturing-related issues. The FDA lists Bravelle as discontinued rather than as an actively marketed U.S. product.[1][2]
The U.S. withdrawal materially changed the commercial outlook:
- Urofollitropin lost its established U.S. branded channel.
- Fertility clinics shifted toward recombinant FSH and other gonadotropins.
- Any U.S. re-entry would require a regulatory and commercial strategy rather than a simple continuation of the former brand.
- The absence of a major U.S. product limits the usefulness of U.S. historical sales as a forecast base.
The FDA’s discontinued-product status does not necessarily mean that the active ingredient is scientifically obsolete. It indicates that the listed product is no longer marketed under its former U.S. approval.
When did urofollitropin lose U.S. commercial exclusivity?
Urofollitropin’s U.S. commercial erosion was driven primarily by product discontinuation and competitive substitution, not by a clearly disclosed wave of generic Paragraph IV launches.
Bravelle was approved in 2004. FDA records identify the product as discontinued. The commercial withdrawal followed the 2015 recall associated with concerns involving potency and assay results. Ferring subsequently announced that Bravelle would not return to the U.S. market.[2][3]
The relevant exclusivity distinction is:
| Exclusivity category |
Urofollitropin position |
| New chemical entity exclusivity |
Not applicable in the conventional small-molecule sense |
| Orphan exclusivity |
Not applicable |
| U.S. biologic reference-product exclusivity |
Not the main commercial issue for Bravelle |
| Pediatric exclusivity |
No material current impact identified |
| Patent exclusivity |
No active U.S. patent barrier is publicly central to current market access |
| Brand exclusivity |
Ended in practical terms when Bravelle was withdrawn |
Urofollitropin is a protein hormone, but its U.S. regulatory history was tied to an NDA rather than the current commercial structure used for newer reference biologics. The principal constraint is the lack of an actively marketed reference product, not a high-value remaining patent term.
What patents protect urofollitropin products?
The commercial patent estate for urofollitropin is limited compared with newer biologics and long-acting fertility products. Core composition claims covering urinary FSH are old. Product differentiation has historically depended more on purification, formulation, dosing, packaging, and manufacturing controls than on new molecular composition.
Potential patent categories include:
- Purification of urinary FSH.
- Removal of urinary proteins and contaminants.
- Stabilized lyophilized formulations.
- Combination protocols involving FSH and other gonadotropins.
- Device or packaging claims.
- Manufacturing and quality-control processes.
- Method-of-use claims for ovarian stimulation.
Publicly available U.S. Orange Book information does not indicate a currently important, enforceable patent listing that blocks a new urofollitropin product. For non-U.S. products, patent status must be assessed jurisdiction by jurisdiction because national registrations, supplementary protection rights, formulation patents, and manufacturing claims can differ.
What is the Orange Book status of Bravelle?
Bravelle’s Orange Book significance is limited because the product is listed as discontinued and is no longer a major U.S. commercial reference point. The absence of active commercial distribution reduces the value of any historical brand or listing strategy.
A future sponsor would face a regulatory pathway assessment involving:
- Whether the product could rely on an abbreviated or suitability-based pathway.
- Whether the reference product remains legally and scientifically usable.
- Whether the product should be developed as a biological product or under an NDA-based approach.
- Whether a new clinical comparability package would be required.
- Whether manufacturing changes would trigger substantial additional FDA review.
The regulatory pathway is a more material issue than a conventional patent cliff.
Are there Paragraph IV challenges or generic launches?
No major current U.S. Paragraph IV campaign against Bravelle is a central market event. The product’s withdrawal removed much of the commercial incentive for a conventional generic challenge.
The more plausible competitive models are:
- International urofollitropin products entering markets through local regulatory approvals.
- Recombinant FSH products competing through established registrations.
- Lower-priced recombinant biosimilar or follow-on FSH products in Europe.
- Hospital, clinic, and pharmacy procurement substitution.
- New fertility products using improved injection devices or longer-acting dosing.
A generic entrant would still face technical hurdles. Urofollitropin is not a simple tablet-scale product. Its source material, purification process, viral and microbial controls, potency assay, glycosylation profile, stability, and batch consistency are important regulatory attributes.
How does urofollitropin compare with recombinant FSH?
Recombinant FSH has become the principal competitive benchmark. Products such as Gonal-f and Follistim have stronger global commercial infrastructure, established fertility-clinic relationships, modern delivery devices, and more predictable supply.
| Factor |
Urofollitropin |
Recombinant FSH |
| Source |
Human urinary extraction |
Recombinant cell culture |
| Manufacturing |
Collection, purification, viral and impurity controls |
Controlled biotechnological production |
| Product consistency |
Depends on source and purification controls |
Generally more standardized |
| Clinical use |
Ovarian stimulation and ovulation induction |
Same broad treatment categories |
| Pricing |
Often competitive in tender or regional markets |
Frequently premium branded pricing |
| U.S. presence |
Bravelle withdrawn |
Strong established presence |
| Patent risk |
Generally mature and limited |
Product, device, formulation, and process patents vary |
| Supply risk |
Dependent on donor-source supply and purification |
Dependent on bioprocess capacity and quality systems |
| Physician preference |
Stronger in selected cost-sensitive markets |
Strong in developed fertility markets |
Clinical evidence has not established a universal superiority of urinary FSH over recombinant FSH. Product selection often reflects protocol design, clinician experience, reimbursement, local availability, and price.[4]
What drives the urofollitropin market?
The market is shaped by the growth of infertility treatment, but urofollitropin captures only a portion of that growth.
Assisted reproductive technology demand
Global IVF activity continues to expand because of delayed childbearing, infertility prevalence, increased fertility awareness, and improved treatment access. FSH products benefit from this underlying demand. The growth does not automatically translate into urofollitropin growth because recombinant products have captured much of the incremental value.
Price and reimbursement
Urofollitropin can compete where fertility drugs are paid through public reimbursement, clinic procurement, or treatment-package pricing. In price-sensitive markets, a urinary-derived product may remain commercially viable if it is materially cheaper than branded recombinant alternatives.
Manufacturing economics
The product’s economics depend on donor-source collection, purification yield, quality testing, cold-chain handling, sterile fill-finish, and batch release. Scale advantages are weaker than for a widely used recombinant product with large manufacturing plants and global volumes.
Distribution
Urofollitropin is more exposed to regional distributors and local registration holders than global recombinant brands. Distributor concentration can affect pricing, inventory, and market continuity.
Clinical protocol changes
Long-acting FSH products, individualized stimulation protocols, anti-Müllerian hormone testing, and improved ovarian-response monitoring can affect unit demand. Better dosing precision may reduce total FSH consumption per cycle even as the number of treatment cycles increases.
What is the financial trajectory for urofollitropin?
No major manufacturer publicly reports standalone global revenue for urofollitropin. Financial analysis must therefore use market position, product availability, and parent-company disclosures rather than a verified product-level revenue series.
The U.S. trajectory is clear:
| Period |
Financial and commercial implication |
| 2004-2014 |
Bravelle generated branded U.S. revenue within Ferring’s fertility portfolio |
| 2015-2016 |
Recall, manufacturing disruption, and withdrawal sharply reduced U.S. revenue |
| 2017 onward |
U.S. urofollitropin revenue became immaterial or absent as a commercial product line |
| Current international period |
Revenue remains regional and depends on local registrations, distributors, and price positioning |
The likely revenue profile is mature to declining in high-income markets, with selective stability or modest growth in emerging fertility markets. The principal upside would come from a low-cost relaunch or expansion in jurisdictions where recombinant FSH pricing is restrictive. The principal downside is continued substitution by recombinant products and increasing regulatory scrutiny of urinary-derived biologics.
A new entrant would need to prove that the product can achieve an acceptable margin after manufacturing controls, clinical development, registration, pharmacovigilance, and fertility-clinic commercialization costs. The market is unlikely to support a premium valuation based solely on the urofollitropin molecule.
Which companies are competing with urofollitropin?
The competitive landscape includes global fertility companies and regional manufacturers.
- Merck Serono competes through Gonal-f and related fertility products.
- Organon competes through Follistim AQ and broader reproductive-health products.
- Gedeon Richter and partners commercialize recombinant FSH products in selected regions.
- Theramex commercializes fertility products in international markets.
- IBSA and regional licensees participate in urinary and recombinant gonadotropin markets.
- Menopur and related menotropin products compete in protocols requiring FSH and LH activity.
The strongest competitors have greater physician reach, broader product portfolios, established reimbursement relationships, and stronger device platforms.
What generic entry risks exist?
Generic or follow-on entry risk is moderate from a regulatory perspective but limited by market size in the United States. The core molecule is mature, yet a sponsor must establish comparability and control the manufacturing process.
Key barriers include:
- Source-material procurement.
- Consistent FSH potency.
- Impurity and contaminant removal.
- Viral safety and microbiological controls.
- Stability of the lyophilized product.
- Sterile manufacturing capacity.
- Local clinical and regulatory requirements.
- Clinic adoption and reimbursement placement.
The commercial risk is that a low-cost entrant may gain share but produce modest revenue because fertility drugs are prescribed within treatment protocols and often selected as part of a broader clinic or manufacturer relationship.
What licensing deals affect urofollitropin?
Publicly disclosed licensing activity is more extensive for recombinant FSH, fertility devices, and broader gonadotropin portfolios than for urofollitropin itself. Regional commercialization agreements remain important because urofollitropin products are often sold through country-specific registration holders and distributors.
The most valuable deal structures would involve:
- Exclusive regional distribution.
- Transfer of a registered product dossier.
- Contract manufacturing or fill-finish.
- Acquisition of fertility portfolios.
- Co-promotion with IVF clinics.
- Supply agreements with public health systems.
There is no broadly disclosed global transaction that gives urofollitropin a clear platform-company valuation comparable with leading recombinant FSH franchises.
What patent litigation and settlement activity affect urofollitropin?
No major current U.S. patent litigation or Paragraph IV settlement involving Bravelle defines the market. Litigation exposure is more likely to arise from manufacturing know-how, product quality, regulatory exclusivity, or regional formulation claims than from a remaining composition-of-matter patent.
For an international launch, due diligence should focus on:
- Local formulation patents.
- Process patents covering purification.
- Manufacturing know-how ownership.
- Trademark rights for Bravelle, Fostimon, and regional brands.
- Regulatory data protection.
- Distribution exclusivity.
- Product liability and recall history.
How strong is the urofollitropin commercial and patent estate?
The commercial estate is weak in the United States and moderate in selected international markets. The patent estate is mature and unlikely to create a durable monopoly. Manufacturing and regulatory execution are more important than patent duration.
| Risk factor |
Assessment |
| U.S. market access |
Weak because Bravelle is discontinued |
| International opportunity |
Selective, market dependent |
| Patent barrier |
Low to moderate |
| Manufacturing barrier |
Moderate to high |
| Reimbursement sensitivity |
High |
| Recombinant competition |
High |
| Product differentiation |
Limited without price or device advantage |
| Revenue visibility |
Low because product-level disclosure is limited |
| Litigation risk |
Low in the current U.S. market |
| Relaunch potential |
Possible but commercially uncertain |
Key Takeaways
- Urofollitropin is a mature urinary-derived FSH product used in fertility treatment.
- Bravelle’s U.S. withdrawal sharply reduced the product’s commercial relevance in the United States.
- International products such as Fostimon remain relevant in selected countries.
- Recombinant FSH products are the main competitive threat.
- No major current Paragraph IV or patent-litigation event drives the market.
- Core molecule patent protection is mature; manufacturing, quality, registration, and distribution are more important barriers.
- Public companies do not generally disclose standalone urofollitropin revenue.
- The financial trajectory is declining or stagnant in developed markets, with selective regional opportunity in price-sensitive markets.
- A relaunch would require a differentiated cost, supply, or distribution strategy.
FAQs About Urofollitropin Market Dynamics
Is urofollitropin still available in the United States?
Bravelle, the principal U.S. urofollitropin product, was discontinued. Current availability of any imported or compounded product would depend on FDA authorization and applicable supply rules.
Is urofollitropin a biosimilar?
Urofollitropin is not generally analyzed as a biosimilar to recombinant follitropin alfa or follitropin beta. The products have different biological sources and manufacturing processes.
Is Fostimon the same as Bravelle?
Both are urofollitropin products, but they are not automatically interchangeable. Approval, formulation, dosage presentation, manufacturing, and regulatory status vary by country.
Can a company relaunch urofollitropin in the United States?
A relaunch would require a viable FDA regulatory pathway, compliant manufacturing, adequate clinical and analytical support, and a commercial strategy against established recombinant FSH products.
What is the main investment risk for urofollitropin?
The main risk is limited commercial differentiation. A sponsor may face high manufacturing and regulatory costs while competing against better-established recombinant FSH products with stronger clinic access and broader portfolios.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Bravelle, NDA 021306. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2015). Ferring Pharmaceuticals announces voluntary nationwide recall of all lots of Bravelle. https://www.fda.gov/
-
Ferring Pharmaceuticals. (2016). Bravelle product information and U.S. commercial status announcements. Ferring Pharmaceuticals.
-
Cochrane Fertility Regulation Group. (2018). Urinary versus recombinant follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology. Cochrane Database of Systematic Reviews. https://www.cochranelibrary.com/
